28. Outcomes of indirect hyperbilirubinemia due to maternal-fetal blood group incompatibility using an IVIG-based protocol at the Vietnam National Children's Hospital
Main Article Content
Abstract
Indirect hyperbilirubinemia (IHB) due to maternal-fetal blood group incompatibility is a primary cause of early and severe jaundice in neonates. According to the American Academy of Pediatrics (AAP), maternal-fetal blood group incompatibility is recognized as a key risk factor for bilirubin-induced encephalopathy.This descriptive study was conducted on 111 neonates with jaundice resulting from maternal-fetal blood group incompatibility at the VietNam National Children’s Hospital. Two groups were evaluated for treatment outcomes of neonates managed with IVIG for IHB : the intravenous immunoglobulin (IVIG) group (n = 82) and the exchange transfusion group (n = 29). . Results showed that jaundice onset occurred within 24 hours post-birth. The predominant cause was maternal-fetal ABO incompatibility (91.5%), followed by Rh incompatibility (2.4%) and minor blood group incompatibility (6.1%). The IVIG group exhibited a shorter hospital stay, with no significant difference in phototherapy duration between the groups. No complication related to IVIG was observed. Compared to the exchange transfusion group, the IVIG group demonstrated a lower complication rate but had a higher incidence of anemia at follow-up.
Article Details
Keywords
Indirect hyperbilirubinemia, neonates, IVIG
References
2. Diala UM, Usman F, Appiah D, et al. Global Prevalence of Severe Neonatal Jaundice among Hospital Admissions: A Systematic Review and Meta-Analysis. J Clin Med. 2023; 12(11): 3738. doi:10.3390/jcm12113738.
3. Kemper AR, Newman TB, Slaughter JL, et al. AAP 2022. Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2022; 150(3).
4. Alsaleem M. Intravenous Immune Globulin Uses in the Fetus and Neonate: A Review. Antibodies Basel Switz. 2020; 9(4): 60. doi:10.3390/antib9040060.
5. Subcommittee on Hyperbilirubinemia. AAP 2004.Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. Pediatrics. 2004; 114(1): 297-316. doi:10.1542/peds.114.1.297.
6. Recommendations | Jaundice in newborn babies under 28 days | Guidance | NICE. May 19, 2010. Accessed May 31, 2025. https://www.nice.org.uk/guidance/cg98/chapter/Recommendations#intravenous-immunoglobulin.
7. Al-Lawama M, Badran E, Elrimawi A, et al. Intravenous Immunoglobulins as Adjunct Treatment to Phototherapy in Isoimmune Hemolytic Disease of the Newborn: A Retrospective Case-Control Study. J Clin Med Res. 2019; 11(11): 760-763. doi:10.14740/jocmr4003.
8. Christensen RD, Bahr TM, Tweddell SM, et al. Diagnosing Anemia in Neonates: An Evidence-Based Approach. NeoReviews. 2023; 24(6): e343-e355. doi:10.1542/neo.24-6-e343.
9. Mohan DR, Lu H, McClary J, et al.Evaluation of Intravenous Immunoglobulin Administration for Hyperbilirubinemia in Newborn Infants with Hemolytic Disease. Children. 2023; 10(3): 496. doi:10.3390/children10030496.
10. Okulu E, Erdeve O, Kilic I, et al. Intravenous Immunoglobulin Use in Hemolytic Disease Due to ABO Incompatibility to Prevent Exchange Transfusion. Front Pediatr. 2022; 10: 864609. doi:10.3389/fped.2022.864609.
11. Pan J, Zhan C, Yuan T, et al. Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study. J Perinatol Off J Calif Perinat Assoc. 2021; 41(6): 1397-1402. doi:10.1038/s41372-021-00963-5.
12. Navarro M, Negre S, Golombek S, et al. Intravenous Immune Globulin: Clinical Applications in the Newborn. NeoReviews. 2010; 11(7): e370-e378. doi:10.1542/neo.11-7-e370.
13. Figueras-Aloy J, Rodríguez-Miguélez JM, Iriondo-Sanz M, et al. Intravenous immunoglobulin and necrotizing enterocolitis in newborns with hemolytic disease. Pediatrics. 2010; 125(1): 139-144. doi:10.1542/peds.2009-0676.
14. Li J, Zhong XY, Song SJ, et al. Is intravenous immunoglobulin a risk factor for necrotizing enterocolitis in neonates with haemolytic disease of the newborn? A retrospective cohort study. Vox Sang. 2022; 117(9): 1098-1104. doi:10.1111/vox.13297.